-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Janux Therapeutics, Lowers Price Target to $29

Benzinga·12/17/2025 17:47:07
语音播报
Barclays analyst Etzer Darout maintains Janux Therapeutics (NASDAQ:JANX) with a Overweight and lowers the price target from $48 to $29.